About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, September 10th, 2015

The QualityStocks
Daily Stock List


Xenetic Biosciences, Inc. (XBIO)

TopPennyStockMovers reported recently on Xenetic Biosciences, Inc. (XBIO), The MicrocapNews and Real Pennies did previously, and today we report on the Company, here at the QualityStocks Daily Newsletter.

Xenetic Biosciences, Inc. is a biopharmaceutical company listed on the OTC Markets’ Group’s OTCQB. The Company is focusing on developing next-generation biologic drugs and novel oncology therapeutics. Its proprietary drug technology platforms include PolyXen®, designed to develop next generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs. The Company’s platforms also include OncoHist™ for the development of novel oncology drugs focused on orphan indications. Xenetic Biosciences is based in Lexington, Massachusetts.

The Company’s lead product candidates include ErepoXen®. This is a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease. Its lead product candidates additionally include OncoHist™. This is a novel recombinant human histone H1.3 molecule for the treatment of refractory Acute Myeloid Leukemia (AML) with the potential to treat many other cancer indications.

Xenetic is collaborating with Russian-based OJSC Pharmsynthez and the Serum Institute of India to test additional drug and vaccine candidates and to de-risk the development process with clinical data generated in Russia and India before Xenetic takes these candidates into the clinic in Western markets. OJSC Pharmsynthez is an affiliate of a significant shareholder in Xenetic Biosciences.

Regarding PolyXen®, it is an enabling platform technology for protein drug delivery. PolyXen® utilizes the natural polymer polysialic acid (PSA) to prolong the drug's half-life and potentially improve the stability of therapeutic peptides and proteins.

Yesterday, Xenetic Biosciences announced that its contracts and arrangements with Baxter Healthcare SA (Baxter SA) and Baxter Healthcare Corp. (together referred to as Baxter) (BAX) have been assigned to Baxalta, Inc.(BXLT) (Baxalta) as part of the spin out of the company’s biopharmaceutical business.

Xenetic Biosciences has an exclusive research, development, license and supply agreement with Baxalta (formerly Baxter Healthcare SA and Baxter Healthcare Corp.) to develop products with an extended half-life of certain proteins and molecules utilizing the Company’s patent protected PolyXen® technology.  

Xenetic Biosciences, Inc. (XBIO), closed Thursday's trading session at $0.4299, up 7.47%, on 69,411 volume with 19 trades. The average volume for the last 60 days is 15,994 and the stock's 52-week low/high is $0.175/$0.75.

OptimizeRx Corp. (OPRX)

Streetwise Reports and Bull in Advantage reported previously on OptimizeRx Corp. (OPRX), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

OTCQB-listed OptimizeRx Corp. provides unique consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products. The Company does so while offering pharmaceutical and healthcare companies effective ways to expand awareness, access and adherence to their medications. The Company’s core product is SampleMD. OptimizeRx is based in Rochester, Michigan.

Its SampleMD replaces drug samples with electronic trial vouchers and copay coupon savings. These are electronically added to an e-Prescription and sent electronically to the pharmacy and is integrated within leading Electronic Health Record (EHR) platforms in the country. These include Allscripts, Quest Diagnostics, Practice Fusion and more than 300 other EHRs to reach over 250,000 healthcare providers.

OptimizeRx promotes patients savings and support from the world's largest pharmaceutical companies. These include Pfizer, Lilly, Novartis, AstraZeneca and many others. Additionally, the Company has launched OPTIMZEHR™. This is its consulting and implementation practice to assist pharmaceutical-biotech companies and healthcare provider platforms in determining and executing on mutually beneficial opportunities to jointly assist physicians and patients within their electronic health record (EHR) workflow.

OptimizeRx’s services include SAMPLEMD® E-Coupons; Patient Education; On-Demand Support; EHR Brand Messaging; New Product Launch/Drug File Integration; and EHR Sales Training. The Company first launched its SampleMD e-coupon solution in April 2015 within Practice Fusion's EMR. OptimizeRx continues to add new brands this year at existing customers, including AstraZenica and Lilly, and also at new customers such as Otsuka and Shionogi.

Last month, OptimizeRx announced, during its earnings conference call, continued growth in expansion of pharmaceutical brands and promotional reach within its increasing network of electronic health records (EHRs) and physicians. During the call, OptimizeRx discussed Q2 results and 2015 activity and recent developments.

The Company had record revenues for Q2 ended June 30, 2015, up 20 percent over the same Q2 of 2014 and a 15 percent increase over Q1 of 2015. It had positive cash flow from operations of roughly $250,000 during the six month period of 2015 with its cash balance increasing to greater than $3.6 million. Its’ working capital was approximately $3.4 million and its working capital ratio was 2.5 to 1. Excluding non-cash expenses, the first six months of 2015 produced operating income of $251,372.

OptimizeRx Corp. (OPRX), closed Thursday's trading session at $0.87, up 2.35%, on 36,000 volume with 27 trades. The average volume for the last 60 days is 18,169 and the stock's 52-week low/high is $0.7623/$1.59.

Royale Globe Holding, Inc. (ROGP)

RedChip reported on Royale Globe Holding, Inc. (ROGP), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

Incorporated in 2006, Royale Globe Holding, Inc. is a development stage company that lists on the OTCQB. The Company is actively considering various acquisition targets and other business opportunities. Royale Globe Holding’s plan of operation for the next 12 months is to explore the acquisition of an operating business or the consummation of a business opportunity.

Previously, Royale Globe Holding operated as an exploration stage mining company. The Company was formerly known as Royale Group Holding, Inc. It changed its corporate name to Royale Globe Holding Inc. in January of 2014. The Company has its headquarters in Bangkok, Thailand.

Royale Globe Holding had acquired a 100 percent interest in a claim on a mineral property situated in the New Westminster, Similkameen, Mining Division of the Province of British Columbia, Canada. It paid approximately $1,500 to keep the claim in good standing through September 8, 2008. Royal Globe did not determine whether this property contained reserves that were economically recoverable and never conducted any exploration of the site. The Company’s rights to the claim expired as of September 8, 2008.

The Company, as it pursues its plan of operation, indicates that it will require additional funding to proceed with any acquisition program or business opportunity. It anticipates that additional funding will be in the form of equity financing from the sale of its common stock or from Director loans. The Company does not have any arrangements in place for any future loans or equity financing.

On March 19, 2015, Ho Shih Khiam became the new Board Director, Secretary and Chief Executive Officer (CEO) of Royale Globe Holding.

This past April, Royale Globe Holding announced that on March 20, 2015, the Company entered into a Share Exchange Agreement with RMC Mining SDN BHD, a company incorporated under the laws of Malaysia (RMC) and Maricom SDN BHD, a company registered under the laws of Malaysia (MARICOM).

With this Agreement, Royale Globe Holding was to issue 600,000,000 shares of common stock to RMC in exchange for 99.6 percent of the total ownership of Maricom. Subsequently, the 600,000,000 shares of the Company's common stock were issued in May of this year.

Royale Globe Holding, Inc. (ROGP), closed Thursday's trading session at $3.00, up 3.80%, on 500 volume with 4 trades. The average volume for the last 60 days is 3,497 and the stock's 52-week low/high is $0.20/$3.90.

Enumeral Biomedical Holdings, Inc. (ENUM)

We are highlighting Enumeral Biomedical Holdings, Inc. (ENUM) today, here at the QualityStocks Daily Newsletter.

Enumeral Biomedical Holdings, Inc. is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. The Company is building a pipeline of immunomodulators for the treatment of cancer and inflammatory diseases and taking advantage of the breadth of its technology through strategic collaborations. Its innovative platform enables it to identify and characterize promising new drugs relevant to cancer, infectious and inflammatory diseases. Enumeral Biomedical Holdings is headquartered in Cambridge, Massachusetts.

Enumeral is enabling and hastening the discovery and development of novel antibody immunotherapies, or immunomodulators, which are validated with its human-driven immune profiling platform. The Company’s immunoprofiling platform harnesses The Power of Human™. Enumeral believes that its cellular functional profiling techniques provide for a deeper understanding of the diversity of human responses and provide a more rational foundation to guide immunotherapy design and development. Its belief is that it has a unique ability to broadly interrogate the human immune microenvironment for candidate selection and validation.

The Company believes its unique capabilities enable it to measure drug effects in a patient-specific manner, providing the foundation for developing best-in-class product candidates, based on a fundamental understanding of how immunotherapies work in each patient. The core technology underlying its platform was developed at, and licensed from, the Massachusetts Institute of Technology, Harvard University, and Whitehead Institute for Biomedical Research and Massachusetts General Hospital.

Enumeral is building a pipeline centered on next-generation checkpoint modulators, with initial targets including PD-1, Tim3, Lag-3, OX40, and VISTA. In developing these agents, its researchers apply a proprietary immune profiling technology platform that measures functioning of the human immune system at the level of individual cells. This provides important insights for candidate selection and validation. The Company aims to move its lead PD-1 antagonist into clinical testing during the second half of 2016, with additional programs moving toward IND-enabling studies.

In January 2015, Enumeral announced that it signed an agreement with Memorial Sloan Kettering Cancer Center. The agreement is part of Enumeral’s Phase II Small Business Innovation Research (SBIR) grant with the National Cancer Institute. The agreement will deploy Enumeral’s human tissue immune-oncology profiling technology at MSK in the laboratory of Jedd D. Wolchok, MD, PhD.  Dr. Wolchok is the Chief of Melanoma and Immunotherapeutics in the Clinical Investigation Department.

This week, Enumeral Biomedical Holdings announced that it achieved the first milestone in its immuno-oncology-focused collaboration with Merck Sharp & Dohme Corp. (Merck). In this collaboration, the parties are applying Enumeral’s Human Approach immune profiling technology to colorectal cancer patient tissues to identify functional cellular responses to immuno-oncology therapies undergoing development by Merck.

Enumeral Biomedical Holdings, Inc. (ENUM), closed Thursday's trading session at $0.50, even for the day, on 44,100 volume with 9 trades. The average volume for the last 60 days is 26,989 and the stock's 52-week low/high is $0.302/$1.8999.

Agritek Holdings, Inc. (AGTK)

SmallCapVoice reported earlier on Agritek Holdings, Inc. (AGTK), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.

Agritek Holdings, Inc. provides ground-breaking, turnkey solutions for medicinal and canna-businesses within regulated jurisdictions across the U.S.  It is the first fully reporting Company and pioneer within the medicinal marijuana space. Agritek does not directly grow, harvest, or distribute or sell cannabis or any substances that violate United States law or the Controlled Substances Act, nor does it have any intention of so doing in the future. Agritek lists on the OTCQB.

Agritek provides unique patient and agricultural solutions. It is working to be the leader in Compassionate Care Technology and indoor/outdoor agricultural solutions for the recreational cannabis industry. It was the first public entity to offer electronically processed transactions within the medicinal marijuana sector.

Agritek distributes vertical business products and services to regulated cannabis businesses. These include consulting and management services related to the purchase and lease of building and land operations within regulated jurisdictions; the Mont Blunt Brand of Vaporizers and e-Cig line; and Hemp based beverages. Additionally, the Company provides equipment leasing and credit facilities for large scale grow and retail operations through its established banking network.

Agritek Holdings has two wholly owned subsidiaries, “Agritek Venture Holdings, Inc.,” which holds all land acquisitions and leases, and “The American Hemp Trading, Inc.,” for hemp based beverages and products. Through Agritek Venture Holdings, it provides real estate services. This includes the acquisition, zoning, and infrastructure build of greenhouse operations and leasing of agricultural land developments zoned specifically for canna-businesses within licensed jurisdictions.

Agritek Holdings has executed and completed the asset acquisition of the entire line of products, technology, and customers of Dry Vapes Holdings, Inc. Dry Vapes’ plan is to roll out the complete product line to more than 5,000 brick and mortar smoke shops nationally. Dry Vapes will continue to be manufactured under the "Mont Blunt™" brand name.

Agritek Holdings has executed an operational and licensing agreement with Green Leaf Farms Holdings, Inc., an 80 percent owned subsidiary of Player's Network (PNTV). The five year agreement provides for Agritek Holdings to be the exclusive consultant concerning the build out on behalf of Green Leaf for the 22,000 sq. ft. facility now under contract for purchase by an investment partner of Green Leaf for $2.8 million. Green Leaf currently has two provisional or "MME" licenses in North Las Vegas, Nevada for medicinal cannabis cultivation and production.

Today, Agritek Holdings announced that it launched its new line of Prohibition Vaporizers and accessories under its' wholly-owned subsidiary Prohibition Products, Inc. The next generation intellectual property (IP) encompasses a proprietary cartridge and battery, which synthesizes herbs for use in a personal portable vaporizer device. The expectation is that the Prohibition Line will be available at brick-and-mortar retailers and online at prohibitionlife.com beginning September 25, 2015.

Agritek Holdings, Inc. (AGTK), closed Thursday's trading session at $0.0029, up 73.65%, on 15,801,609 volume with 220 trades. The average volume for the last 60 days is 1,066,263 and the stock's 52-week low/high is $0.0016/$0.145.


The QualityStocks
Company Corner


Fresh Promise Foods, Inc. (FPFI)

The QualityStocks Daily Newsletter would like to spotlight Fresh Promise Foods, Inc. (FPFI). Today, Fresh Promise Foods, Inc. closed trading at $0.0002, even for the day, on 20,749,989 volume with 27 trades. The stock’s average daily volume over the past 60 days is 16,016,473, and its 52-week low/high is $0.0002/$0.165.

Fresh Promise Foods, Inc. (FPFI) is a consumer products and marketing company operating in the high-margin multi-billion dollar health and wellness food and beverage sectors. The company sets itself apart from the competition by marrying innovative technology and product development with perceptive marketing and sales service strategy.

Through wholly-owned subsidiary Harvest Soul, Inc., FPFI produces the world's first USDA organic, Non-GMO Project verified chewable juice products. Utilizing some of the world's healthiest ingredients, the company creates a nutritionally-dense combination of fiber-rich vegetables and fruits mixed with tasty bits of chewable seeds, nuts and berries. By encouraging chewing during consumption, these revolutionary juices have been shown to jumpstart digestion and promote improved nutrient absorption.

Since launching its chewable juice products online in December 2014, the company has made considerable progress in expanding upon its market presence. As of its latest update, FPFI had secured placement in all 32 Whole Foods Market locations in its five-state southern region and entered into a distribution agreement with San Francisco-based Optimum Sales in order to expand its distribution footprint to include the West Coast and Pacific Northwest.

According to a report by the Organic Trade Association, sales of organic food and non-food products in the United States exceeded $39 billion in 2014, representing an increase of 11.3 percent over the previous year. As FPFI continues to expand its national distribution network, the company should be in a strong strategic position to leverage this market performance in order to promote sustainable growth.

FPFI is also committed to expanding its presence in the organic foods industry by investing in businesses that have identified a unique niche in the health and wellness sector. Through its ventures and emerging brands segment, the company looks to provide senior management support to pre-revenue or early-stage firms with an established leadership team and a passion for food, health and wellness. Disclaimer

Fresh Promise Foods, Inc. Company Blog

Fresh Promise Foods, Inc. News:

Fresh Promise Foods, Inc. Consolidates Debt to Reduce Obligations and Dilution

The Litchfield Fund Announces Investment in Harvest Soul

Harvest Soul Organic Juices Expanding to West Coast

Hemp, Inc. (HEMP)

The QualityStocks Daily Newsletter would like to spotlight Hemp, Inc. (HEMP). Today, Hemp, Inc. closed trading at $0.054, off by 10.00%, on 2,959,292 volume with 211 trades. The stock’s average daily volume over the past 60 days is 294,004, and its 52-week low/high is $0.05/$1.00.

Hemp, Inc. was pleased to announce today that David Schmitt, Chief Operating Officer (COO) of Hemp, Inc.'s subsidiary, Industrial Hemp Manufacturing, LLC, has been elected to the North Carolina Industrial Hemp Association (NCIHA) Board of Directors for the 2015-2016 term. NCIHA has been a key driving force, for over a year, in trying to legalize hemp in the state of North Carolina. The association also serves as a hub for current industry information and development in North Carolina for "farmers, processors, retailers, consumers, and educational/governmental stakeholders."

Hemp, Inc. (HEMP) is engaged in the research and development of all things made of industrial hemp. From fabric, paper, cosmetics, food and jewelry to pulp, fuel, paints and more, the application of hemp represents a myriad of possibilities. The company strategizes to recognize the profits that could be made in making the world a better place through the industrial commercialization of this resource.

Hemp, Inc. subsidiaries include Industrial Hemp Manufacturing, LLC, which will soon be offering DrillWall™ for maintaining the seals on drilling for water, oil, gas and any other liquid or gas; and The Industrial Hemp and Medical Marijuana Consulting Company, Inc., which pulls pertinent market information from a vast network of professionals, specialists and experts from various niches of the hemp industry.

Las Vegas-based Hemp, Inc. conducts its operations through its 70,000-square-foot processing plant and decortication line of equipment, which is useful manufacturing more than 50,000 commercial products. The company's current line of offerings include hemp-infused body candles, shampoo and conditioner, smoothies, jewelry, healing oils, twine, lip balm and skin moisturizers.

Hemp products are used all over America every day and are sold in the largest and most respected stores. Not to be confused with marijuana, hemp does not contain psychoactive compounds and is legal in the United States and most of the world. Hemp, Inc.'s mission is to educate the public on this important differentiation while working to expand corporate infrastructure and invest in profitable, legal and diversified ventures poised to bring reward and value to shareholders. Disclaimer

Hemp, Inc. Company Blog

Hemp, Inc. News:

Hemp, Inc. Subsidiary's COO, David Schmitt, Elected to the North Carolina Industrial Hemp Association (NCIHA) Board of Directors

Hemp, Inc. Reports 2nd Quarter 2015 Financial Results

Hemp, Inc. Partners With The Silver Tour to Expand Its Market Awareness Campaign

Growblox Sciences, Inc. (GBLX)

The QualityStocks Daily Newsletter would like to spotlight Growblox Sciences, Inc. (GBLX). Today, Growblox Sciences, Inc. closed trading at $0.34, up 13.71%, on 244,332 volume with 44 trades. The stock’s average daily volume over the past 60 days is 59,714, and its 52-week low/high is $0.151/$1.51.

Growblox Sciences, Inc. (GBLX), a biopharmaceutical research and development company, is focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies for various medical conditions. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.

The company’s GrowBLOX technology suite includes the TissueBLOX, GrowBLOX, and CureBLOX equipment. Together, these components provide unparalleled control and monitoring of cannabis cultivation throughout the plant's life-cycle. These patent pending processes were designed to produce a safe and consistent cannabis product under cGMP guidelines. Utilizing a computer-regulated system that optimizes the nutrients, water, temperature, and gas levels, the GrowBLOX suite produces cannabis with more active ingredients per pound than traditional cultivation methods.

Also, based on an analysis of preclinical and clinical data from thousands of peer-reviewed studies, Growblox Sciences has identified the most effective profiles of cannabinoids and terpenes for the treatment of conditions within seven therapeutic categories. As a result of this extensive research and the analysis of the active ingredient profiles of 30,000 Cannabis strains in conjunction with a major testing lab, the company will be able to provide patients with natural cannabis strains containing the ideal ratios for treating specific diseases or symptoms.

Another significant advantage held by the company stems from an accelerated drug development program to finish in 3-5 years instead of the 15-20 years typically seen in traditional pharmaceutical development programs. Armed with an intellectual property strategy that takes full advantage of the design of the GrowBLOX technology suite and protects the valuable foundation laid, Growblox Sciences has positioned itself well for long-term success in the burgeoning cannabis space. Disclaimer

Growblox Sciences, Inc. Company Blog

Growblox Sciences, Inc. News:

GrowBLOX Sciences Appoints Former Nevada State Senator Sandra Tiffany as New General Manager

GrowBLOX Sciences Appoints New CFO John Poss

GrowBLOX Sciences is Making Big Moves in Anticipation of Opening Nevada Cultivation Facility

Galenfeha, Inc. (GLFH)

The QualityStocks Daily Newsletter would like to spotlight Galenfeha, Inc. (GLFH). Today, Galenfeha, Inc. closed trading at $0.31, up 10.71%, on 277,618 volume with 67 trades. The stock’s average daily volume over the past 60 days is 67,288, and its 52-week low/high is $0.1011/$4.00.

Galenfeha, Inc. (GLFH) is an engineering, product development, and manufacturing company that provides innovative solutions for oil and natural gas production, as well as stored energy products across a number of different industries. The company provides these products and services through its stored energy and oil & gas division.

Through its stored energy division, Galenfeha offers one of the most powerful, environmentally friendly battery systems in the market. The batteries have onboard computers, are inherently safe, internally temperature regulated, have optional GPS monitoring capabilities, offer significant weight reduction of up to 50%, and are engineered specifically for each type of application. Features include 100% “green” chemistry, RoHS compliancy, and active short circuit protection control.

Through its oil and gas division, the company offers chemical injection pumps that merge the perceived benefits of a hybrid, electric over pneumatic system. Galenfeha management believes the combination of the two parameter control systems represents a measurable shift in efficiency, reliability, cost management, and profitability to individual well locations as well as entire production fields. The combined technologies have demonstrated increased chemical injection accuracy, reducing chemical contamination in the production process while controlling cost and waste.

The company’s unwavering dedication is to continuously develop products that perform better than conventional solutions while also reducing environmental impact. Leveraging the management team’s wealth of resources and relationships, Galenfeha is well positioned for continued growth as the company aims to expand in both the stored energy and oil & gas industries. Disclaimer

Galenfeha, Inc. Company Blog

Galenfeha, Inc. News:

Galenfeha Announces Exclusive West Texas Distributor

Galenfeha, Inc. Products Offered by Leading Power and Automation Company

Galenfeha Stored Energy Solutions Enters Aviation Industry

View Systems, Inc. (VSYM)

The QualityStocks Daily Newsletter would like to spotlight View Systems, Inc. (VSYM). Today, View Systems, Inc. closed trading at $0.0045, up 9.76%, on 722,585 volume with 8 trades. The stock’s average daily volume over the past 60 days is 457,663, and its 52-week low/high is $0.0035/$0.0178.

View Systems, Inc. (VSYM) is a leading security technology products company with “state-of-the-art” technological solutions for modern security problems. Targeting the challenging business opportunities in the opening decades of the 21st century and beyond, View Systems has solutions for law enforcement facilities such as correctional institutions as well as other government agencies, schools, courthouses, event and sports venues, the military and commercial businesses.

The senior management team is comprised of successful businessmen with decades of business and professional experience in the security industry. The approach used by View Systems utilizes the expertise of this team to provide innovative solutions to security problems with reliable “cutting edge” products in conjunction with client-oriented security consulting services.

The company’s flagship product, ViewScan, is an advanced walk-through Concealed Weapons Detection System (CWD) that greatly simplifies the process of discriminating suspicious items from harmless ones. The highly sensitive, completely passive sensor technology powering the system accurately detects the location and number of threat objects such as knives, guns and razor blades while ignoring personal artifacts like coins, keys and belt buckles. A portable version of this system has only a fifteen minute setup time using only a screwdriver and it easily fits inside a golf size case.

Experts say the security industry has been the fastest-growing sector of the global economy during the past decade. Today, it is conservatively estimated to be a $100 billion-a-year industry and growing. As the business environment continues to get more complex, especially in foreign markets, View Systems is strategically positioned to capitalize on unsurpassed opportunity. Disclaimer

View Systems, Inc. Company Blog

View Systems, Inc. News:

View Systems in Discussions With Three M&A Candidates and Reviewing Letter of Intent

View Systems, Inc. Files for Patent, Begins Manufacturing of Enhanced ViewScan Product

View Systems Continues to Install Its Proprietary Scanning Systems Nationwide


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters







Investor News Source

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251